254 related articles for article (PubMed ID: 21814507)
1. Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.
Mészáros B; Tóth J; Vértessy BG; Dosztányi Z; Simon I
PLoS Comput Biol; 2011 Jul; 7(7):e1002118. PubMed ID: 21814507
[TBL] [Abstract][Full Text] [Related]
2. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions.
Gey van Pittius NC; Sampson SL; Lee H; Kim Y; van Helden PD; Warren RM
BMC Evol Biol; 2006 Nov; 6():95. PubMed ID: 17105670
[TBL] [Abstract][Full Text] [Related]
3. targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis.
Raman K; Yeturu K; Chandra N
BMC Syst Biol; 2008 Dec; 2():109. PubMed ID: 19099550
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
5. PGRS Domain of Rv0297 of
Sharma T; Singh J; Grover S; P M; Firdos F; Alam A; Ehtesham NZ; Hasnain SE
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502303
[No Abstract] [Full Text] [Related]
6. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
Lou Z; Zhang X
Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
[TBL] [Abstract][Full Text] [Related]
7. Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
Uddin R; Siddiqui QN; Sufian M; Azam SS; Wadood A
Genes Genomics; 2019 Nov; 41(11):1281-1292. PubMed ID: 31388979
[TBL] [Abstract][Full Text] [Related]
8. PE_PGRS proteins of
De Maio F; Berisio R; Manganelli R; Delogu G
Virulence; 2020 Dec; 11(1):898-915. PubMed ID: 32713249
[TBL] [Abstract][Full Text] [Related]
9. In Silico Drug Target Discovery Through Proteome Mining from M. tuberculosis: An Insight into Antivirulent Therapy.
Bhattacharya S; Ghosh P; Banerjee D; Banerjee A; Ray S
Comb Chem High Throughput Screen; 2020; 23(3):253-268. PubMed ID: 32072892
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints.
McEvoy CR; Cloete R; Müller B; Schürch AC; van Helden PD; Gagneux S; Warren RM; Gey van Pittius NC
PLoS One; 2012; 7(4):e30593. PubMed ID: 22496726
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Comparative Proteomic Analysis of Aminoglycosides Resistant and Susceptible Mycobacterium tuberculosis Clinical Isolates for Exploring Potential Drug Targets.
Sharma D; Kumar B; Lata M; Joshi B; Venkatesan K; Shukla S; Bisht D
PLoS One; 2015; 10(10):e0139414. PubMed ID: 26436944
[TBL] [Abstract][Full Text] [Related]
13. Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.
Hosen MI; Tanmoy AM; Mahbuba DA; Salma U; Nazim M; Islam MT; Akhteruzzaman S
Interdiscip Sci; 2014 Mar; 6(1):48-56. PubMed ID: 24464704
[TBL] [Abstract][Full Text] [Related]
14. Proteome-wide lysine acetylation profiling of the human pathogen Mycobacterium tuberculosis.
Xie L; Wang X; Zeng J; Zhou M; Duan X; Li Q; Zhang Z; Luo H; Pang L; Li W; Liao G; Yu X; Li Y; Huang H; Xie J
Int J Biochem Cell Biol; 2015 Feb; 59():193-202. PubMed ID: 25456444
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis: a model system for structural genomics.
Smith CV; Sacchettini JC
Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
[TBL] [Abstract][Full Text] [Related]
16. PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Gupta A; Pal SK; Pandey D; Fakir NA; Rathod S; Sinha D; SivaKumar S; Sinha P; Periera M; Balgam S; Sekar G; UmaDevi KR; Anupurba S; Nema V
Ann Clin Microbiol Antimicrob; 2017 Aug; 16(1):56. PubMed ID: 28821299
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Certain Well-Characterized Domains of Known Functions within the PE and PPE Proteins of Mycobacteria.
Sultana R; Tanneeru K; Kumar AB; Guruprasad L
PLoS One; 2016; 11(2):e0146786. PubMed ID: 26891364
[TBL] [Abstract][Full Text] [Related]
18. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
19. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
[TBL] [Abstract][Full Text] [Related]
20. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA.
Goulding CW; Perry LJ; Anderson D; Sawaya MR; Cascio D; Apostol MI; Chan S; Parseghian A; Wang SS; Wu Y; Cassano V; Gill HS; Eisenberg D
Biophys Chem; 2003 Sep; 105(2-3):361-70. PubMed ID: 14499904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
